Blog Posts

Diego Díaz García: Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials

Diego A. Díaz García/X

Jun 22, 2025, 11:09

Diego Díaz García: Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials

Diego Díaz García, Medical Oncologist, CEO and Founder of CánCare, posted on X:

“Are we overestimating success in ph3 oncology trials?

Only 6% of ph3 oncology RCTs show improvement in both OS and QoL.

Most “positive” trials rely on surrogate endpoints, often without adjusting QoL for baseline. We must refocus trials on what truly matters to patients.”

Title: Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials

Authors: Alexander D. Sherry, Avital M. Miller, Jnana Preeti Parlapalli, Gabrielle S. Kupferman, Esther J. Beck, Jordan McDonald, Ramez Kouzy, Joseph Abi Jaoude, Timothy A. Lin, Nina N. Sanford, Fumiko Chino, Bishal Gyawali, Christopher Booth, Pavlos Msaouel, Ethan B. Ludmir

Read The Full Article at JAMA Oncology.

Diego Díaz García: Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials

More posts featuring Diego Díaz García.

Alexander D. Sherry Avital M Miller Bishal Gyawali cancer Christopher Booth Diego Díaz García Esther J Beck Ethan B Ludmir Fumiko Chino Gabrielle S Kupferman Jnana Preeti Parlapalli Jordan McDonald Joseph Abi Jaoude Nina N. Sanford OncoDaily Oncology Pavlos Msaouel Ramez Kouzy Timothy A Lin

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Writer?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen

Top 10 Immunotherapy Trials in Lung Cancer to Watch at ESMO 2025

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...